[FOR HCP AUDIENCE] Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast, developed for health care providers, will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

Topics:

• Clinical Advances in BCMA-directed Bispecific Antibody Therapy
• Clinical Advances in GPRC5D-directed Bispecific Antibody Therapy
• Considerations for Selecting Bispecific Antibody Therapy for RRMM Management
• Mitigating CRS During Bispecific Antibody Therapy
• Mitigating Infections During Bispecific Antibody Therapy
• Mitigating GPRC5D-directed Bispecific Antibody Therapy-related Adverse Events
• Role of APPs in Helping the Patient During Bispecific Antibody Treatment
• Emerging Bispecific Antibody Constructs and New Combinations

This episode is supported by Johnson & Johnson and Pfizer, Inc.

To view the virtual roundtable on the management of bispecific antibody–associated adverse events, visit myCME.

To learn more about the Multiple Myeloma Research Foundation (MMRF), visit www.themmrf.org.

Let your patients and their caregivers know about the FREE myeloma resources available on the MMRF Education Hub.